Latest Diabetes News

Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Adheris Health has achieved cashflow break-even in Q4 FY26 following a strategic reset focused on its US operations, cutting costs by over 30% and repositioning for growth in FY27 with a stronger digital pipeline.

Hearts and Minds Investments Limited (HM1) saw its profit after tax drop 57% to $46.4 million for FY26, amid a portfolio return slowdown to 5.2%. The company declared a 10-cent fully franked final dividend and maintained its $11.4 million commitment to Australian medical research.

Recce Pharmaceuticals has secured ethics approval to add an active-controlled arm to its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, enabling head-to-head comparison against existing antibiotics.

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Proteomics International has locked in a three-year exclusive distribution deal with Healius, leveraging its extensive pathology network to roll out its Promarker® diagnostic tests nationally from FY27.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.